All posts by: Michael Zand

First US Gene Therapy, Approved for Vision Loss, to Cost $850000 – Xconomy

XconomyFirst US Gene Therapy, Approved for Vision Loss, to Cost $850000XconomyThe first gene therapy approved in the United States will cost $850,000, its developer Spark Therapeutics (NASDAQ: ONCE) announced today. Spark hopes to reduce the sticker sh… Continue reading

Drug Firm Spark Therapeutics Will Charge $850000 for Vision-Loss Gene Therapy – Wall Street Journal

Wall Street JournalDrug Firm Spark Therapeutics Will Charge $850000 for Vision-Loss Gene TherapyWall Street JournalSpark Therapeutics Inc. ONCE 4.60% said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision… Continue reading

Should patients—not the FDA— have final say on risky gene therapy … – Genetic Literacy Project

Genetic Literacy Project

Should patients—not the FDA— have final say on risky gene therapy … Genetic Literacy Project Working with mice, researchers have used gene therapy to restore sight to the blind, reprogram the body’s own T cells to attack cancerous tumors, prevent t.